INC Research/inVentiv now Syneos Health

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/manaemedia)
(Image: iStock/manaemedia)
INC Research/inVentiv Health is starting the new year with a rebrand after merging to create one of the largest biopharmaceutical outsourcing providers in 2017.

The company​, with a combined staff of more than 21,000 employees across more than 60 counties, will now be known as Syneos Health, Inc., effective January 4, 2018.

Syneos Health common shares will trade on the Nasdaq Global Select Market under the new ticker symbol “SYNH” by January 9, 2018.

"Since close, we’ve quickly assembled an Integrated Solutions Group, bringing together seasoned industry product strategists with regulatory, clinical, commercial and real world expertise​," Alistair Macdonald, CEO of Syneos Health told Outsourcing-Pharma.com.

"This group is working with customers across the small to mid to large continuum to determine the right mix of clinical and commercial capabilities to produce a higher likelihood of launch success,​” he added. 

Also this week, the company announced that Greg Rush is stepping down as chief financial officer (CFO) to pursue a different opportunity. The company has initiated the search for a replacement.

The current executive vice president and CFO of the company’s commercial solutions business will be appointed as interim CFO at the end of April if a replacement has not been found, according to the company.

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers